The goal of present study was to demonstrate inflammatory rebound defined from the systemic inflammatory response syndrome (SIRS) criteria after discontinuation of cisatracurium.
The criteria for recurrent episodes of acute cystitis were rebound LUTI symptoms with a positive bacteriological urine culture.
Inflammatory rebound was defined as the increase of SIRS by at least 1 criterion from the baseline defined as the cisatracurium discontinuation.
The criteria for defining a recurrent episode of cystitis were rebound lower urinary tract infection symptoms with pyuria and positive bacteriological urine culture.
Hepatitis B virus reactivation was defined as a rebound of serum HBV DNA ≥10-fold the baseline level, which means a narrow criterion of reactivation.
The model is based on the criteria for predicting whether two solid particles will stick together or rebound from each other subsequent to impact while immersed in the fluid.
Number of criterion like toxin reduction ratio, dialysis adequacy based on Kt/Vurea, and post-dialytic rebound can be used.
Participants who received EFV were primarily nonresponders because of adverse events, stopping criteria, or virologic rebounds (50 to <400 copies/ml), with no treatment-emergent mutations.
